logo

EbookBell.com

Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.

Please read the tutorial at this link:  https://ebookbell.com/faq 


We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.


For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.

EbookBell Team

Anticancer Agents Frontiers In Cancer Chemotherapy 1st Edition Iwao Ojima

  • SKU: BELL-2609368
Anticancer Agents Frontiers In Cancer Chemotherapy 1st Edition Iwao Ojima
$ 31.00 $ 45.00 (-31%)

4.1

90 reviews

Anticancer Agents Frontiers In Cancer Chemotherapy 1st Edition Iwao Ojima instant download after payment.

Publisher: American Chemical Society
File Extension: PDF
File size: 3.34 MB
Pages: 380
Author: Iwao Ojima, Gregory D. Vite, Karl-Heinz Altmann
ISBN: 9780841237452, 084123745X
Language: English
Year: 2001
Edition: 1

Product desciption

Anticancer Agents Frontiers In Cancer Chemotherapy 1st Edition Iwao Ojima by Iwao Ojima, Gregory D. Vite, Karl-heinz Altmann 9780841237452, 084123745X instant download after payment.

Describes cutting edge approaches in the development of anticancer agents for chemotherapy. These new and interdisciplinary approaches are aimed at the development of tumor specific anticancer agents while increasing the potency against drug-resistant tumors. The volume includes an overview of new paradigms for cancer drug discovery and development by NCI, new generation cytotoxic agents, mechanism based enzyme inhibitors as anticancer agents, anti-angiogenesis agents, antitumor vaccines, and tumor activated prodrugs using immunoconjugates of monoclonal antibodies with cytotoxic agents.

Related Products